Q1 2024 · 13F-HR
Cormorant Asset Management, LPholdings as filed
Filed 2024-05-15 · accession 0001583977-24-000002
$2.28B
Reported value
57
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $426.7M | 18.7% | 8,494,151 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $142.5M | 6.25% | 6,893,235 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $123.8M | 5.43% | 1,780,000 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $107.0M | 4.69% | 2,700,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $99.0M | 4.34% | 3,203,029 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $79.9M | 3.51% | 1,310,000 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $79.5M | 3.49% | 2,025,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $77.8M | 3.41% | 2,139,102 | Common | SOLE |
| 54300N103 | — | LONGBOARD PHARMACEUTICALS IN | $72.4M | 3.18% | 3,353,141 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $54.8M | 2.41% | 3,006,534 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $53.8M | 2.36% | 1,150,000 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $53.4M | 2.34% | 3,570,872 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $47.6M | 2.09% | 529,170 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $46.8M | 2.05% | 685,000 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $42.2M | 1.85% | 6,616,667 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $39.6M | 1.73% | 1,711,460 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $35.5M | 1.56% | 1,500,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $35.1M | 1.54% | 800,000 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $35.0M | 1.54% | 3,142,079 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $33.7M | 1.48% | 616,963 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $32.2M | 1.41% | 715,000 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $31.6M | 1.39% | 1,069,796 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $30.5M | 1.34% | 2,130,000 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $30.3M | 1.33% | 2,909,000 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $29.4M | 1.29% | 3,250,000 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $28.6M | 1.26% | 1,250,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $28.2M | 1.24% | 750,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $27.4M | 1.20% | 538,714 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $26.4M | 1.16% | 1,182,563 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $23.8M | 1.05% | 550,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $23.5M | 1.03% | 400,000 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $21.1M | 0.92% | 2,125,000 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $19.7M | 0.87% | 450,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $18.8M | 0.82% | 1,100,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $18.3M | 0.80% | 1,300,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $16.9M | 0.74% | 1,000,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $15.6M | 0.68% | 575,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $14.9M | 0.65% | 2,710,000 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $14.6M | 0.64% | 1,350,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $13.5M | 0.59% | 625,000 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $11.6M | 0.51% | 2,600,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $11.0M | 0.48% | 5,560,300 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $10.9M | 0.48% | 440,000 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $9.9M | 0.43% | 300,000 | PUT | SOLE |
| 45254E107 | IMRX | IMMUNEERING CORP | $9.5M | 0.42% | 3,295,273 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $9.5M | 0.42% | 250,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $9.2M | 0.40% | 515,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $8.1M | 0.35% | 300,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $7.8M | 0.34% | 125,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $6.3M | 0.28% | 561,600 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $6.3M | 0.28% | 593,043 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $5.8M | 0.25% | 427,163 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $4.7M | 0.20% | 75,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $4.6M | 0.20% | 350,000 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $4.5M | 0.20% | 496,750 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $4.3M | 0.19% | 1,394,336 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $4.0M | 0.18% | 1,170,870 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.